Modulation of inflammatory changes in early stages of colon cancer through activation of PPARγ by diclofenac

European Journal of Cancer Prevention

Volumn 19, Issue 5, 2010, Pages 319-327

  Kaur, Jasmeet ^a   Sanyal, Sankar Nath ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

apoptosis; cyclooxygenase 2; diclofenac; nuclear factor jB (p65); peroxisome proliferator activated receptor

Indexed keywords

1,2 DIMETHYLHYDRAZINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ANTINEOPLASTIC AGENT; CARCINOGEN; CYCLOOXYGENASE 2 INHIBITOR; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER STAGING; CHEMICALLY INDUCED; COLONIC NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CARCINOGENS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DISEASE MODELS, ANIMAL; INFLAMMATION; INTESTINAL MUCOSA; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; NF-KAPPA B; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 77955270210     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32833ad385     Document Type: Article

References (43)

1. Alam CAS, Seed MP, Willoughby DA (1995). Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with Hyaluronan. J Pharm Pharmacol 47:407-411.
2. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Brockman JA, Gupta RA, Dubois RN (1998). Activation of PPARg leads to inhibition of anchorage independent growth of human colorectal cancer cells. Gastroenterology 115:1049-1055.
4. Chan FK, Hung LC, Suen BY (2002). Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104-2110.
5. Chang TH, Szabo E (2000). Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor g in non-small cell lung cancer. Cancer Res 60:1129-1138.
6. Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, Zackert WE, et al. (1999). Prostaglandin J2 and 15-deoxy-d12, 14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 59:2739-2746.
7. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchierii G, et al. (2000). Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-g and nuclear factor-kB. J Biol Chem 275:32681-32687.
8. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W (1993). Positive regulation of the peroxisome beta-oxidation pathway by fatty acids through activation of peroxisome proliferaor-activated receptors (PPAR). Biol Cell 77:67-76.
9. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, VanDePutte LBA, et al. (1998). Cyclooxygenase in biology and disease. FASEB J 12:1063-1073.
10. Elder DJE, Paraskeva C (1998). COX-2 inhibitors for colorectal cancer. Nat Med 4:392-393.
11. Figureras A, Capella D, Castel JM, Laporte JR (1994). Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 47:297-303.
12. Freudlsperger C, Moll I, Schumacher U, Thies A (2006). Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anti-Cancer Drugs 17:325-332.
13. Hagos GK, Carroll RE, Kouznetsova T, Li Q, Toader V, Fernandez PA, et al. (2007). Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo. Mol Cancer Ther 6:2230-2239.
14. Harper D (1994). A review of current clinical trials with HYAL CT-1101, HYALAT- 2101 and HYALAV-2201. R Soc Med Round Table Ser 33:60-63.
15. Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM (2008). The role of PPARg in the cyclooxygenase pathway in lung cancer. PPAR Res 2008:1-7.
16. Ikawa H, Kameda H, Kamitani H, Baek SJ, Nixon JB, His LC, et al. (2001). Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res 267:73-80.
17. Inoue H, Tanabe T, Umesono K (2000). Feedback control of cyclooxygenase-2 expression through PPARg. J Biol Chem 275:28028-28032.
18. Kanwar SS, Vaiphei K, Nehru B, Sanyal SN (2008). Antioxidative effects of non-steroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rat. J Environ Pathol Toxicol Oncol 27:89-100.
19. Kaur J, Sanyal SN (2009). Association of PI3-kinase and Wnt signaling in nonsteroidal anti-inflammatory drug-induced apoptosis in experimental colon cancer. Am J Biomed Sci 1:395-405.
20. Kaur J, Sanyal SN (2010a). Induction of apoptosis as potential chemopreventive effect of dual cyclooxygenase inhibitor, diclofenac in early colon carcinogenesis. J Environ Pathol Toxicol Oncol 29:41-53.
21. Kaur J, Sanyal SN (2010b). Oxidative stress and stress-signaling in chemoprevention of early colon cancer by diclofenac. Am J Biomed Sci 2:63-78.
22. Kliewer SA, Umesono K, Noonan D, Heyman R, Evans RM (1992). Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774.
23. Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M, et al. (2000). Lipopolysaccharide increases cyclooxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kB activation. Oncogene 19:1225-1231.
24. Lemberger T, Desvergne B, Wahli W (1996). Peroxisome proliferaor- activated receptors: a nuclear receptor signalling pathway in lipid physiology. Annu Rev Cell Dev Biol 12:335-363.
25. Lynch NR, Castes M, Astoin M, Salomon JC (1978). Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer 38:503-512.
26. Mouille B, Robert V, Blachier F (2004). Adaptive increase of ornithine production and decrease of ammonia metabolism in rat colonocytes and hyperproteic diet ingestion. Am J Physiol Gastrointest Liver Physiol 287: G344-G351.
27. Patel MJ, Stockfleth E (2007). Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol 156:53-56.
28. Placha W, Gil D, Dembinska-Kiec A, Laidler P (2003). The effect of PPARg ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13:447-456.
29. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS (2002). Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62:65-70.
30. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002). Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146:94-100.
31. Roediger WE, Truelove SC (1979). Method of preparing isolated colonic epithelial cells (colonocytes) for metabolic studies. Gut 20:484-488.
32. Sarraf P, Mueller E, Smith WM,Wright H, Kum J, Aaltonen L, et al. (1999). Lossof-function mutations in PPARg associated with human colon cancer. Molecular Cell 3:799-804.
33. Seed MP, Brown JR, Freemantle CN, Papwethr JL, Colville-Nash PR, Willis D, et al. (1997). The inhibitor of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 57:1625-1629.
34. Shi S, Klotz U (2008). Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64:233-252.
35. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM (2002). Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 14:1101-1111.
36. Steele VE, Wargovich MJ, Pereira MA, Rao CV, Lubet RA, Reddy BS, et al. (1999). Comparison of the azoxymethane (AOM)-induced rat colon crypt assay with the rat colon tumor assay of cancer chemopreventive agents. Proc Am Assoc Cancer Res 40:A377.
37. Subbaramaiah K, Dannenberg AJ (2003). Cyclooygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102.
38. Tontonoz P, Hu E, Spiegelman BM (1994). Stimulation of adipogenesis in fibroblasts by PPARgamma 2, a lipid-activated transcription factor. Cell 79:1147-1156.
39. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CDM, et al. (1997). Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferaor g and the retinoid X receptor. Proc Natl Acad Sci 94:237-241.
40. Tsuji M, Dubois RN (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:49-501.
41. Turner D, Berkel HJ (1993). Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Can Med Assoc J 149:595-602.
42. Voutsadakis IA (2007). Peroxisome proliferator-activated receptor g (PPARg) and colorectal carcinogenesis. J Cancer Res Clin Oncol 133:917-928.
43. Yang WL, Frucht H (2001). Activation of PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22:1379-1383.